The Role of PCSK9 in Cardiovascular Risk

This chapter explores the influence of PCSK9 on LDL levels and cardiovascular risk, highlighting the efficacy of PCSK9 inhibitors in reducing LDL levels and associated cardiovascular disease risk. It discusses the initial high expectations and subsequent disappointment regarding PCSK9 inhibitors' impact on cardiovascular risk reduction. The chapter also delves into Mendelian randomization studies comparing the effects of PCSK9 gene variants with other gene variants on cardiovascular risk reduction per unit change in LDL.